| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Insulin-like growth factor-binding protein 6, IBP-6, IGF-binding protein 6, IGFBP-6, IGFBP6, IBP6 |
| Entrez GeneID | 3489 |
| WB Predicted band size | 25.3kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This IGFBP6 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 176-200 amino acids from the C-terminal region of human IGFBP6. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,1%BSA and 50% glycerol.prepared by Saturated Ammonium Sulfate (SAS) . |
+ +
以下是关于IGFBP6抗体的3篇模拟参考文献示例(仅供参考，具体文献需通过学术数据库检索确认)：
---
1. **文献名称**: "Immunohistochemical analysis of IGFBP6 expression in human leukemia"
**作者**: Bach LA, et al.
**摘要**: 该研究通过免疫组化技术分析了IGFBP6在急性髓系白血病(AML)患者骨髓样本中的表达水平，发现IGFBP6高表达与白血病细胞分化程度相关，提示其可能作为疾病进展的潜在标志物。
2. **文献名称**: "IGFBP6 antibody-based detection in breast cancer tissues and its prognostic significance"
**作者**: Wang Y, et al.
**摘要**: 研究利用IGFBP6特异性抗体对乳腺癌组织进行检测，发现IGFBP6低表达与肿瘤转移和患者生存率降低显著相关，表明其可能参与抑制乳腺癌侵袭的分子机制。
3. **文献名称**: "Functional characterization of IGFBP6 antibody in blocking cancer cell migration"
**作者**: Kim S, et al.
**摘要**: 通过体外实验验证IGFBP6抗体对头颈鳞状细胞癌细胞迁移的抑制作用，证实IGFBP6通过调控IGF-1信号通路影响肿瘤细胞的运动能力。
---
**备注**：以上为模拟摘要，实际文献需通过PubMed、Google Scholar等平台以关键词“IGFBP6 antibody”或“IGFBP6 function”检索。近年研究可能涉及IGFBP6在凋亡、自噬或靶向治疗中的机制。
Insulin-like growth factor-binding protein 6 (IGFBP6) is a member of the IGFBP family that regulates the bioavailability and activity of insulin-like growth factors (IGFs), particularly IGF-2. It binds IGFs with high affinity, modulating their interaction with cell surface receptors and influencing cellular processes like proliferation, differentiation, and apoptosis. IGFBP6 is unique among IGFBPs due to its preferential binding to IGF-2 over IGF-1 and its role in inhibiting IGF-mediated signaling pathways. Dysregulation of IGFBP6 has been implicated in cancer, fibrosis, and metabolic disorders, making it a biomarker of interest in disease research.
Antibodies targeting IGFBP6 are essential tools for studying its expression, localization, and function. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and ELISA to quantify IGFBP6 levels in tissues or biological fluids. Polyclonal and monoclonal IGFBP6 antibodies are available, often validated for specificity across human, mouse, or rat samples. These antibodies help elucidate IGFBP6's role in tumor suppression, particularly in cancers like ovarian, glioblastoma, and leukemia, where its downregulation correlates with disease progression. Additionally, they aid in exploring therapeutic strategies targeting the IGF axis. Proper validation, including knockout controls and cross-reactivity checks, is critical for ensuring experimental reliability.
×
